EQRXW
Sign in
EQRx, Inc.
Save
1.14B
Market cap
–
Current P/E
–
Forward P/E
About
Health care
Sector
Biotechnology
Industry
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. Its product pipeline in development includes Aumolertinib, an EGFR inhibitor for the treatment of ? EGFR-mutated? non-small cell lung cancer (NSCLC); Sugemalimab, an anti-PD-L1 antibody for the treatment of ?stage III and IV ?
Similar securities
Based on sector and market capitalization
Report issue